Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

NCT05514444 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Solid Tumors
Neoplasms

Interventions

BIOLOGICAL: MK-4464
BIOLOGICAL: Pembrolizumab
DRUG: 89Zr-MK-4464

Sponsor

Merck Sharp & Dohme LLC